OS Therapies (NYSE: OSTX) is a cancer immunotherapy company engaged in the development of new treatments for osteosarcoma and other solid tumors.
OS Therapies is actively advancing its osteosarcoma immunotherapy: CEO Paul Romness
Categories
Biotechnology
Illumina (ILMN) expects adjusted EPS of approximately $4.50 for FY25
Biotechnology company Illumina, Inc. (NASDAQ: ILMN) has issued fresh earnings guidance for fiscal 2025, to reflect tariff-related challenges to export. The company
Earnings Summary: Moderna slips to loss in Q4; revenue down 66%
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) has reported a net loss for the fourth quarter of 2024, compared to a profit last
Key metrics from Biogen’s (BIIB) Q4 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its fourth quarter 2024 earnings results today. Total revenue increased 3% year-over-year to $2.5 billion. Net
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net
LLY Earnings: Eli Lilly Q4 2024 profit more than doubles; revenue up 45%
Eli Lilly and Company (NYSE: LLY) Thursday reported a sharp increase in its fourth-quarter revenues. The pharmaceutical company's adjusted earnings more than
MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided
AbbVie Q4 2024 adjusted earnings decline despite 6% revenue growth
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced fourth-quarter 2024 financial results, reporting a double-digit dip in adjusted earnings and an increase in
Earnings Summary: DexCom reports preliminary Q4 2024 results
DexCom, Inc. (NASDAQ: DXCM) has announced preliminary financial results for the fourth quarter of 2024, reporting an 8% increase in revenues. The
NeOnc Technologies plans to go public through direct listing
NeOnc Technologies Holdings Inc., a privately held clinical-stage biotechnology company that develops therapies to improve the treatment of brain tumors and central
Walgreens Boots Alliance expected to report mixed Q1 2025 results
For Walgreens Boots Alliance, Inc. (NASDAQ: WBA), 2024 was a challenging year as it lost market share to competitors and closed several
“Gelteq has been continuously evolving to expand applications and audiences”
Gelteq Limited (NASDAQ: GELS) is a healthcare company specializing in the development and manufacturing of edible gel products, with a focus on
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company
Earnings Summary: A snapshot of CooperCompanies (COO) Q4 2024 results
Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the fourth quarter of 2024, reporting an increase in revenues and
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that
Earnings Summary: Moderna swings to profit in Q3 on modest revenue growth
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) Thursday reported net income for the third quarter of 2024, compared to a loss last year
Key metrics from Bristol Myers Squibb’s (BMY) Q3 2024 earnings results
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues
Key highlights from Biogen’s (BIIB) Q3 2024 earnings results
Biogen Inc. (NASDAQ: BIIB) reported its third quarter 2024 earnings results today. Total revenue decreased 3% year-over-year to $2.46 billion. Revenues were
Abbott Laboratories (ABT) Q3 2024 Earnings: Key financials and quarterly highlights
Abbott Laboratories (NYSE: ABT) reported third quarter 2024 earnings results today. Total reported sales increased 4.9% year-over-year to $10.6 billion. Organic sales
TRxADE Health changes its name to Scienture Holdings
Trxade Health, Inc. (NASDAQ: MEDS), a leading health services IT company, and its wholly owned subsidiary Scienture, LLC revealed that Trxade has
IPO News: Everything you need to know about BioAge Labs’ IPO
BioAge Labs, Inc. is the latest among the healthcare companies pursuing stock-market listing this year. In a registration statement filed with the